Cooper Co (COO) AI Stock Analysis

• Market Cap: $16.29B
• Dividend Yield: N/A
• Average Volume (3M): 2.81M
• Price to Earnings (P/E): 44.4
• Beta (1Y): 0.73
• Revenue Growth: 5.06%
• EPS Growth: -4.47%
• Country: US
• Employees: 16,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.15
• Shares Outstanding: 195,978,030
• 10 Day Avg. Volume: 1,875,772
• 30 Day Avg. Volume: 2,812,655
• PEG Ratio: -7.35
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 3.42
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 4.09
• Enterprise Value/Gross Profit: 6.10
• Enterprise Value/Ebitda: 15.16
• 1Y Price Target: $90.33
• Price Target Upside: 8.66% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): 4.52
• Revenue Forecast (FY): $4.32B

• Rating: 77 Outperform
• Price Target: $94.00 ▲(13.08% Upside)

Cooper Co's overall stock score reflects strong financial health and positive technical indicators, supported by strategic growth initiatives and robust earnings performance. While the valuation is relatively high, the company's focus on share repurchases and debt reduction enhances its long-term financial outlook. Challenges in certain markets, particularly in China, and the absence of a dividend yield are notable risks.

Positive Factors

Revenue Growth

Consistent revenue growth in CooperVision indicates strong market demand and effective product strategies, supporting long-term business expansion.

Balance Sheet Health

A strong balance sheet with reduced debt enhances financial stability and provides flexibility for strategic investments and growth initiatives.

Leadership and Governance

The appointment of an experienced director signals a commitment to strong governance and strategic alignment, potentially driving long-term shareholder value.

Negative Factors

Profit Margin Pressure

Declining profit margins may indicate rising costs or pricing pressures, which could impact profitability if not addressed.

Market Challenges in Asia

Stagnant growth in key markets like China could limit overall expansion and revenue potential, requiring strategic adjustments.

Gross Margin Decline

A decline in gross margins due to external factors like tariffs can affect profitability and may necessitate cost management strategies.

Cooper Co Business Overview & Revenue Model

Company Description

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

How the Company Makes Money

Cooper Co generates revenue through multiple key streams, including direct sales of its consumer goods through retail channels, online marketplaces, and wholesale distribution. The company also engages in strategic partnerships with major retailers and e-commerce platforms, which provide significant exposure and increased sales volume. Additionally, Cooper Co invests in brand development and marketing initiatives to enhance product visibility and consumer loyalty, thereby driving repeat purchases. The company also explores licensing agreements for its products, allowing for additional revenue through royalties while expanding its market reach.

Cooper Co Financial Statement Overview

Summary

Cooper Co exhibits strong financial health with consistent revenue growth and a robust balance sheet characterized by low leverage. While profitability margins have faced some pressure, the company maintains a solid cash flow position. The reduction in debt enhances financial stability, but the declining return on equity and profitability margins warrant close monitoring.

Income Statement

Cooper Co has demonstrated consistent revenue growth over the years, with a recent growth rate of 1.154% in the latest period. The gross profit margin remains strong at over 65%, indicating efficient cost management. However, the net profit margin has slightly decreased to 9.16% from the previous year's 10.07%, suggesting some pressure on net profitability. The EBIT and EBITDA margins have also seen a decline, which could be a concern if the trend continues.

Balance Sheet

The company's balance sheet is robust, with a significant reduction in total debt, leading to a current debt-to-equity ratio of 0.0, down from 0.319 in the previous year. This indicates a strong equity position and reduced financial risk. However, the return on equity has decreased to 0.0%, which may suggest inefficiencies in generating returns from shareholders' equity.

Cash Flow

Cooper Co's cash flow statement shows a healthy operating cash flow of $796.1 million, with a free cash flow growth rate of 5.293%. The free cash flow to net income ratio is currently at 0.0, indicating that the company is generating sufficient cash relative to its net income. However, the operating cash flow to net income ratio is also at 0.0, which could imply potential issues in converting net income into cash.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.05B	4.09B	3.90B	3.59B	3.31B	2.92B
Gross Profit	2.71B	2.48B	2.60B	2.36B	2.14B	1.96B
EBITDA	1.09B	1.05B	1.07B	885.90M	878.70M	823.90M
Net Income	407.80M	374.90M	392.30M	294.20M	385.80M	2.94B
Balance Sheet
Total Assets	12.38B	12.39B	12.32B	11.66B	11.49B	9.61B
Cash, Cash Equivalents and Short-Term Investments	124.90M	110.60M	107.60M	120.90M	138.20M	95.90M
Total Debt	2.48B	2.78B	2.58B	2.57B	2.76B	1.48B
Total Liabilities	4.02B	4.16B	4.23B	4.11B	4.32B	2.66B
Stockholders Equity	8.35B	8.24B	8.08B	7.55B	7.17B	6.94B
Cash Flow
Free Cash Flow	411.90M	433.70M	288.10M	215.00M	450.40M	524.20M
Operating Cash Flow	816.30M	796.10M	709.30M	607.50M	692.40M	738.60M
Investing Cash Flow	-515.70M	-372.90M	-764.60M	-449.00M	-1.83B	-450.30M
Financing Cash Flow	-289.90M	-425.90M	39.20M	-173.90M	1.19B	-311.40M

Cooper Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 83.13
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COO, the sentiment is Positive. The current price of 83.13 is above the 20-day moving average (MA) of 82.45, above the 50-day MA of 77.05, and above the 200-day MA of 74.53, indicating a bullish trend. The MACD of 1.63 indicates Positive momentum. The RSI at 59.79 is Neutral, neither overbought nor oversold. The STOCH value of 77.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COO.

Cooper Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COO	77 Outperform	$16.29B	44.36	4.59%	―	5.06%	-4.47%
HOLX	76 Outperform	$16.70B	30.16	11.12%	―	1.74%	-25.29%
WST	68 Neutral	$19.80B	40.81	16.94%	0.32%	4.90%	-0.26%
ATR	60 Neutral	$8.03B	19.85	15.80%	1.50%	2.50%	25.05%
MASI	54 Neutral	$7.41B	-13.00	-17.93%	―	-16.03%	-813.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAX	47 Neutral	$10.64B	-39.68	-4.70%	2.75%	-21.20%	-325.40%

Cooper Co Corporate Events

Cooper Co strikes board-refresh pact with Browning West

On December 22, 2025, CooperCompanies entered into a cooperation agreement with investment firm Browning West, under which the company appointed veteran medical device executive Walter M. Rosebrough Jr. to its board and its Corporate Governance and Nominating Committee, effective January 3, 2026. The deal commits Cooper to supporting Rosebrough’s election at the 2026 annual meeting, conducting a Browning West–approved search for an additional independent director with medical technology experience by June 30, 2026, capping the board at ten members during the agreement term, and giving due consideration to naming Rosebrough board chair by the end of 2026, while Browning West agrees to standstill and voting commitments, including backing the company’s full slate in 2026. The move, announced in a December 23, 2025 press release, effectively aligns Cooper with an influential shareholder, brings in a director with a strong track record of value creation in the medical device sector, and signals further board refreshment aimed at strengthening governance and supporting long-term shareholder value.

The most recent analyst rating on (COO) stock is a Hold with a $88.00 price target. To see the full list of analyst forecasts on Cooper Co stock, see the COO Stock Forecast page.

Cooper Co Announces Leadership Change Amid Financial Growth

On December 4, 2025, CooperCompanies announced that Robert S. Weiss resigned as Chairman of the Board, effective January 2, 2026, with Colleen E. Jay appointed as his successor. The company also reported its financial results for the fiscal fourth quarter and full year ending October 31, 2025, showing a 5% increase in revenue to $4.1 billion and a 12% rise in non-GAAP EPS to $4.13, despite a 4% decline in GAAP EPS. The company aims to drive long-term shareholder value through growth, profitability, and strategic investments.

The most recent analyst rating on (COO) stock is a Buy with a $88.00 price target. To see the full list of analyst forecasts on Cooper Co stock, see the COO Stock Forecast page.